Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.

Ian Douglas PavordSalman SiddiquiAlberto PapiJonathan CorrenLawrence D SherPhilip BardinDavid LangtonHae-Sim ParkMegan S RiceYamo DenizPaul RoweHeribert W StaudingerNaimish PatelMarcella RuddyNeil M H GrahamAriel Teper

Published in: Journal of asthma and allergy (2020)

Dupilumab reduced severe exacerbations and improved lung function, asthma control and quality of life in patients with elevated baseline eosinophils irrespective of baseline ICS dose or FEV1% predicted.

Keyphrases

lung function
chronic obstructive pulmonary disease
cystic fibrosis
air pollution
atopic dermatitis
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
early onset
replacement therapy